Comparisons to the standard of care TOP1 inhibitor irinotecan revealed that LMP400 resulted in tumor regression in fewer PDX models, suggesting a potential therapeutic liability of this class of agents in this disease. The gene discussed is TOP1; the disease is neoplasm.